Tychan has successfully completed Phase-1 safety trials for Tyzivumab, its first-in-class monoclonal antibody (mAb) therapeutic for Zika, in Singapore.
Tyzivumab was found to be safe and well tolerated up to the highest dose tested. This paves the way for this antibody to be tested in Zika patients in a Phase 1B study for which Tychan has received regulatory approval from the Health Sciences Authority of Singapore. Recruitment of patients is ongoing for this study.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
The technology platform for these studies were developed by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT) /Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong, Deputy Director, Emerging Infectious Diseases Programme, Duke-NUS Medical School, Singapore and Co-Director, Viral Research and Experimental Medicine Centre@SingHealth Duke-NUS (ViREMiCS), with the basic research funded by National Research Foundation (NRF), Singapore.
Temasek Foundation Ecosperity (TF Ecosperity) also provided funding support for the development of this rapid response capability platform, in line with its objective to enhance liveability in Singapore and other cities.
"Demonstration of the safety of Tyzivumab is an important milestone that puts Tychan firmly on a path towards a true rapid response capability for emerging infectious diseases that is so critically needed to overcome the threats of increasing epidemics that have often caused great misery to human lives and severe economic impact," said Teo Ming Kian, Chairman of the Board, Tychan.